IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients
Study Details
Study Description
Brief Summary
Although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by COVID-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome. IL-6, a kind of pleiotropic cytokine, is expressed by immune cells such as DC, monocytes, macrophages, B cells, and subsets of activated T cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a public health emergency of international concern the epidemic has put public health systems under severe strain both in western countries and in the developing world. SARS-CoV-2 displays a more efficient transmission pattern when compared with SARS-CoV and MERS-CoV. Although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by COVID-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome.
IL-6, a kind of pleiotropic cytokine, is expressed by immune cells such as DC, monocytes, macrophages, B cells, and subsets of activated T cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes. It contributes to the pathogenesis of inflammatory or autoimmunity diseases. Excessive production of IL-6 leads to serious disease progression in viral infection. The IL-6 gene is located on chromosome 7 and several polymorphisms have been reported. The most frequently studied polymorphism is the single nucleotide polymorphism (SNP) 174C and - 174G in the promoter region, which has been associated with transcription rates of IL6. The incidence of IL-6-174C alleles is approximately 40%among the general Population. The G allele 174 SNP is coupled with the increased transcription upon endotoxin and IL-1β stimulation, IL-6 -174C allele carrier status is associated with higher level of IL-6 production and more severe forms of 4 pneumonia in general. This analysis strengthens the notion that IL-6 plays a pivotal role in novel coronavirus pneumonia (NCP) progression, it was IL-6-174 C allele rather than G allele that contributed to the risk of sepsis induced by Pneumonia
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| mild group Amendment to MOH COVID-19 Protocol: Patient with mild clinical symptoms & clinically table. CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line. |
Diagnostic Test: interleuken 6 level measurment
Detection of IL6 level using ELISA technique.
Diagnostic Test: Interleukin-6 Gene-174C detection
The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
|
| moderate group Amendment to MOH COVID-19 Protocol: Patient with non-specific and specific respiratory infection (pneumonia). CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening). |
Diagnostic Test: interleuken 6 level measurment
Detection of IL6 level using ELISA technique.
Diagnostic Test: Interleukin-6 Gene-174C detection
The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
|
| severe group Amendment to MOH COVID-19 Protocol: Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air). Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours. CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening). |
Diagnostic Test: interleuken 6 level measurment
Detection of IL6 level using ELISA technique.
Diagnostic Test: Interleukin-6 Gene-174C detection
The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
|
Outcome Measures
Primary Outcome Measures
- interleuken- 6 gene (174G/C) single nucleotide polymorphism ["through study completion, an average of 4 months]
the correlation between IL- 6 gene (174G/C) single nucleotide polymorphism with the pathogenesis of COVID-19 severity in Egyptian patients.
Secondary Outcome Measures
- interleukin 6 level ["through study completion, an average of 4 months]
the correlation between IL-6 with the pathogenesis of COVID-19 severity in Egyptian patients.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients proved to be COVID-19 positive
-
clinical correlation with positive PCR.
-
clinical correlation with positive rapid antigen detection test.
Exclusion Criteria:
-
Patients with chronic infections including hepatitis B or C infection.
-
Immunodeficiency virus (HIV) infections.
-
Autoimmune diseases including systemic lupus erthromatosus and rheumatoid arthritis.
-
Any malignancy or chronic inflammation
-
Any other chest diseases (TB)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Bsant Safwat Kasem | Tanta | El Gharbyia | Egypt | 31527 |
Sponsors and Collaborators
- Tanta University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IL6 in egyptian COVID patients